Many tumors are depleted of mitochondrial DNA; this depletion is associated with changes in gene expression and with the incidence of critical somatic mutations and alterations.
A previously suggested expression signature based on thirteen TP53 transcriptional target genes does not predict the response of wild type TP53 tumors to TP53-MDM2 inhibitors.
Overexpression of BAG2—a novel mutant p53 binding protein—in tumors inhibits MDM2-mediated mutant p53 degradation, which leads to the accumulation of mutant p53 protein and promotes tumorigenesis.